Description:
Aging is the primary risk factor for major chronic diseases, driving demand for clinically relevant preclinical models. In this webinar, we will review the aging therapeutics landscape and introduce Biocytogen’s humanized and knockout (KO) animal models—spanning both physiological and accelerated aging systems. Join us to learn how these models advance mechanistic research, disease tracking, and therapeutic efficacy and safety evaluations.
What you will discover:
• Key biological and physiological features of natural aging mouse models
• Development and validation of accelerated aging mouse models
• Humanized models for senotherapeutic drug discovery, including senescent cell tracing, clearance, and target validation
Speaker:
Meiqi Zhang, Ph.D Product Manager
Dr. Meiqi Zhang received her PhD in Peking University majoring in the mechanism of copper chaperone proteins and the application of copper chaperone antagonists in tumor metal immunology. She subsequently joined Biocytogen as a Product Manager in the BioMice Product Department. Dr. Zhang manages the development of humanized mouse models for neurological disorders and mice models aiding large molecular drugs penetrating blood-brain barrier. A series of humanized mouse models has been successfully implemented across diverse therapeutic areas, including Alzheimer's disease, Parkinson's disease, ALS, epilepsy and some other rare diseases.
